Business
Cocrystal Pharma Insiders Purchase $1.03 Million in Private Placement Priced At-the-Market Under Nasdaq Rules
Investment by Directors and Management demonstrates confidence in the Company Potential for an additional $1.8 million upon the exercise in full of warrants BOTHELL, Wash., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (the “Company” or “Cocrystal”) announces the completion of a private placement of units priced at-the-market under Nasdaq rules with 743,024 shares of its common stock at a purchase price of $1.39 per unit for proceeds of $1.03 million and unregistered wa
About this update from Opko Health, Inc.
[{"type":"image","alt":"Cocrystal Pharma, Inc.","displaySize":"","headline":null,"caption":"Cocrystal Pharma, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":232,"url":"https://media.zenfs.com/en/globenewswire.com/08f29bc54b812697c4622bc8896492a4"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/4LbLeZJiqXTiA4cMc21_YQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTMyNTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/08f29bc54b812697c4622bc8896492a4","width":300,"height":232}},"lazy":false},{"type":"text","content":"Investment by Directors and Management demonstrates confidence in the Company","length":77,"tagName":"p"},{"type":"text","content":"Potential for an additional $1.8 million upon the exercise in full of warrants","length":78,"tagName":"p"},{"type":"text","content":"BOTHELL, Wash., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (the “Company” or “Cocrystal”) announces the completion of a private placement of units priced at-the-market under Nasdaq rules with 743,024 shares of its common stock at a purchase price of $1.39 per unit for proceeds of $1.03 million and unregistered warrants to purchase up to 1,486,048 shares of common stock at an exercise price of $1.24 per share. The warrants are exercisable upon issuance and will expire in 27 months.","length":514,"tagName":"p"},{"type":"text","content":"The four Investors in the private placement are Cocrystal Directors Phillip Frost, M.D., who co-founded the Company and serves as Chairman and CEO of OPKO Health, Inc., Fred Hassan, who is Chairman of the investment firm Caret Group and Director of the private equity firm Warburg Pincus and Richard Pfenniger, and Cocrystal co-CEO and CFO James Martin.","length":353,"tagName":"p"},{"type":"text","content":"“It’s gratifying to join these distinguished board members, who are respected industry veterans, in a shared our commitment to advancing Cocrystal’s mission of addressing the global need for novel antiviral therapies,” said Mr. Martin. “These investments have strengthened our balance sheet as we approach key milestones in our antiviral clinical programs.”","length":357,"tagName":"p"},{"type":"text","content":"The potential additional proceeds to the Company from the warrants, if fully exercised on a cash basis, will be approximately $1.83 million. No assurance can be given that any o...